Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonius de Boer

Showing results (271-280 of 282) with videos related to

Pageof 29
Sort By:
The New England Journal of Medicine|September 4, 2019
A Genotype-Guided Strategy for Oral P2Y<sub>12</sub> Inhibitors in Primary PCIDaniel M F Claassens, Gerrit J A Vos, Thomas O Bergmeijer, et al.
Melanoma Research|December 22, 2020
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastasesRawa K Ismail, Nienke O Sikkes, Michel W J M Wouters, et al.
International Journal of Cancer|June 20, 2020
Real-world outcomes of advanced melanoma patients not represented in phase III trialsMichiel C T van Zeijl, Rawa K Ismail, Liesbeth C de Wreede, et al.
Melanoma Research|June 15, 2022
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitorsRawa K Ismail, Karijn P M Suijkerbuijk, Anthonius de Boer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2021
Adjuvant treatment for melanoma in clinical practice - Trial versus realityMelissa M de Meza, Rawa K Ismail, Daan Rauwerdink, et al.
Plos One|March 10, 2012
Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clampJana V van Vliet-Ostaptchouk, Timon W van Haeften, Gijs W D Landman, et al.
Clinical Pharmacology and Therapeutics|December 4, 2018
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 IndividualsElisa Danese, Sara Raimondi, Martina Montagnana, et al.
Lancet (London, England)|May 22, 2012
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyBenjamin F Voight, Gina M Peloso, Marju Orho-Melander, et al.
Lancet (London, England)|March 17, 2012
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis, Daniel I Swerdlow, Michael V Holmes, et al.
Lancet (London, England)|September 29, 2014
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, et al.
Pageof 29

Showing results (271-280 of 282) with videos related to

Sort By:
Pageof 29
The New England Journal of Medicine|September 4, 2019
A Genotype-Guided Strategy for Oral P2Y<sub>12</sub> Inhibitors in Primary PCIDaniel M F Claassens, Gerrit J A Vos, Thomas O Bergmeijer, et al.
Melanoma Research|December 22, 2020
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastasesRawa K Ismail, Nienke O Sikkes, Michel W J M Wouters, et al.
International Journal of Cancer|June 20, 2020
Real-world outcomes of advanced melanoma patients not represented in phase III trialsMichiel C T van Zeijl, Rawa K Ismail, Liesbeth C de Wreede, et al.
Melanoma Research|June 15, 2022
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitorsRawa K Ismail, Karijn P M Suijkerbuijk, Anthonius de Boer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2021
Adjuvant treatment for melanoma in clinical practice - Trial versus realityMelissa M de Meza, Rawa K Ismail, Daan Rauwerdink, et al.
Plos One|March 10, 2012
Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clampJana V van Vliet-Ostaptchouk, Timon W van Haeften, Gijs W D Landman, et al.
Clinical Pharmacology and Therapeutics|December 4, 2018
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 IndividualsElisa Danese, Sara Raimondi, Martina Montagnana, et al.
Lancet (London, England)|May 22, 2012
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyBenjamin F Voight, Gina M Peloso, Marju Orho-Melander, et al.
Lancet (London, England)|March 17, 2012
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis, Daniel I Swerdlow, Michael V Holmes, et al.
Lancet (London, England)|September 29, 2014
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, et al.
Pageof 29